Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-UMIN000040789
JPRN-UMIN000040789
Completed
未知

The usefulness of immune checkpoint inhibitors among lung cancer patients with driver gene mutants - The usefulness of immune checkpoint inhibitors among lung cancer patients with driver gene mutants

Yokohama City University0 sitesJune 16, 2020
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsung cancer

Overview

Phase
未知
Intervention
Not specified
Conditions
ung cancer
Sponsor
Yokohama City University
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 16, 2020
End Date
July 28, 2020
Last Updated
2 years ago
Study Type
Others,meta-analysis etc
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •Patients who excluded from clinical trials

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer other than adenocarcinoma or squamous cell carcinoma: multicenter retrospective observational studyon-small cell lung cancer other than adenocarcinoma or squamous cell carcinoma
JPRN-UMIN000037777Hamamatsu University School of Medicine60
Recruiting
Not Applicable
A real-world study of efficacy and safety of Immune check point inhibitors in patients with non-small cell lung cancer harboring driver oncogene excepting EGFR
JPRN-UMIN000049022orth East Japan Study Group870
Completed
Not Applicable
Efficacy and safety of immune checkpoint inhibitors alone or in combination with chemotherapy in pulmonary sarcomatoid carcinomaPulmonary sarcomatoid carcinoma
JPRN-UMIN000046002Kobe University124
Not yet recruiting
Not Applicable
Administration of immune checkpoint inhibitors through an elastomeric pump. A patient preference study and cost analysis.Solid tumors for which nivolumab or pembrolizumab monotherapy has an EMA approved indication. This includes (but is not limited to) melanoma, renal-cell cancer, NSCLC and head and neck cancer.
NL-OMON25676Erasmus MC390
Active, not recruiting
Phase 1
Patient preference for administration of cancer immunotherapy via an elastomeric pump. A patient preference study and an economic analysis.Solid tumors for which nivolumab or pembrolizumab monotherapy is an EMA approved indication. This includes (but is not limited to) melanoma, renal-cell cancer, NSCLC and head and neck cancer.Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2021-000058-24-NLErasmus MC Cancer Institute390